Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.99
Viridian Therapeutics, Inc.\DE incurred convertible notes of 250,000,000 with U.S. Bank Trust Company, National Association at 1.75% maturing May 15, 2032.
- Instrument
- convertible notes
- Principal
- 250,000,000
- Counterparty
- U.S. Bank Trust Company, National Association
- Rate
- 1.75%
- Maturity
- May 15, 2032
- Event
- incurrence
Exact text from the filing
On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Viridian Therapeutics, Inc.\DE entered into Indenture with U.S. Bank Trust Company, National Association valued at $250,000,000 aggregate principal amount (effective 2026-05-11).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Value
- $250,000,000 aggregate principal amount
- Effective
- 2026-05-11
Exact text from the filing
On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.
View on SEC.gov